Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas.
Adenocarcinoma, Clear Cell
/ metabolism
Adenocarcinoma, Mucinous
/ metabolism
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Collagen Type III
/ metabolism
Disease Progression
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Middle Aged
Ovarian Neoplasms
/ metabolism
Prognosis
Proteins
/ metabolism
Receptors, G-Protein-Coupled
/ metabolism
Young Adult
Clear-cell ovarian cancer
Immunohistochemistry
Mucinous ovarian cancer
Ovarian cancer
Prognostic biomarker
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Sep 2019
18 Sep 2019
Historique:
received:
14
04
2019
accepted:
23
08
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
14
2
2020
Statut:
epublish
Résumé
Ovarian cancer is the main cause of gynecological cancer-associated death. However, 5-year survival rates differ dramatically between the five main ovarian carcinoma histotypes. Therefore, we need to have a better understanding of the mechanisms that promote histotype-specific ovarian carcinogenesis and identify novel prognostic biomarkers. Here, we evaluated the prognostic role of 29 genes for early-stage (I and II) ovarian carcinomas (n = 206) using immunohistochemistry (IHC). We provide evidence of aberrant protein expression patterns for Collagen type III alpha 1 chain (COL3A1), G protein-coupled receptor 158 (GPR158) and PITH domain containing 1 (PITHD1). Kaplan-Meier survival analysis revealed that COL3A1 expression was associated with shorter overall survival in the four major histotypes of epithelial ovarian carcinoma patients (P value = 0.026, HR = 2.99 (95% CI 1.089-8.19)). Furthermore, GPR158 and PITHD1 were shown to be histotype-specific prognostic biomarkers, with elevated GPR158 expression patterns in mucinous ovarian carcinoma patients with unfavorable overall survival (P value = 0.00043, HR = 6.13 (95% CI 1.98-18.98)), and an association with lower PITHD1 protein expression and unfavorable overall and disease-specific survival in clear-cell ovarian carcinoma patients (P value = 0.012, HR = 0.22 (95% CI 0.058-0.80); P value = 0.003, HR = 0.17 (95% CI 0.043-0.64)). The novel biomarkers identified here may improve prognostication at the time of diagnosis and may assist in the development of future individualized therapeutic strategies for ovarian carcinoma patients.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer is the main cause of gynecological cancer-associated death. However, 5-year survival rates differ dramatically between the five main ovarian carcinoma histotypes. Therefore, we need to have a better understanding of the mechanisms that promote histotype-specific ovarian carcinogenesis and identify novel prognostic biomarkers.
METHODS
METHODS
Here, we evaluated the prognostic role of 29 genes for early-stage (I and II) ovarian carcinomas (n = 206) using immunohistochemistry (IHC).
RESULTS
RESULTS
We provide evidence of aberrant protein expression patterns for Collagen type III alpha 1 chain (COL3A1), G protein-coupled receptor 158 (GPR158) and PITH domain containing 1 (PITHD1). Kaplan-Meier survival analysis revealed that COL3A1 expression was associated with shorter overall survival in the four major histotypes of epithelial ovarian carcinoma patients (P value = 0.026, HR = 2.99 (95% CI 1.089-8.19)). Furthermore, GPR158 and PITHD1 were shown to be histotype-specific prognostic biomarkers, with elevated GPR158 expression patterns in mucinous ovarian carcinoma patients with unfavorable overall survival (P value = 0.00043, HR = 6.13 (95% CI 1.98-18.98)), and an association with lower PITHD1 protein expression and unfavorable overall and disease-specific survival in clear-cell ovarian carcinoma patients (P value = 0.012, HR = 0.22 (95% CI 0.058-0.80); P value = 0.003, HR = 0.17 (95% CI 0.043-0.64)).
CONCLUSIONS
CONCLUSIONS
The novel biomarkers identified here may improve prognostication at the time of diagnosis and may assist in the development of future individualized therapeutic strategies for ovarian carcinoma patients.
Identifiants
pubmed: 31533654
doi: 10.1186/s12885-019-6084-4
pii: 10.1186/s12885-019-6084-4
pmc: PMC6751742
doi:
Substances chimiques
Biomarkers, Tumor
0
COL3A1 protein, human
0
Collagen Type III
0
GPR158 protein, human
0
PITHD1 protein, human
0
Proteins
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
928Subventions
Organisme : Cancerfonden
ID : CAN 2018/417
Organisme : Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer
ID : 2017:144
Organisme : Stiftelsen Assar Gabrielssons Fond
ID : FB 17-08, FB 18-69
Références
Biomed Pharmacother. 2004 Jan;58(1):24-38
pubmed: 14739059
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Gynecol Oncol. 2007 Mar;104(3):508-15
pubmed: 17113137
Front Biosci. 2008 Jan 01;13:1857-65
pubmed: 17981673
Mol Cell Proteomics. 2008 Oct;7(10):2019-27
pubmed: 18669619
Comput Biol Chem. 2008 Dec;32(6):462-8
pubmed: 18757239
Gynecol Oncol. 2009 Jan;112(1):40-6
pubmed: 18851871
Nat Rev Drug Discov. 2011 Jan;10(1):47-60
pubmed: 21193867
Cancer. 2012 Jun 15;118(12):3087-94
pubmed: 22072418
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Virchows Arch. 2012 Mar;460(3):237-49
pubmed: 22322322
Nat Rev Genet. 2012 Mar 13;13(4):227-32
pubmed: 22411467
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273
Tumour Biol. 2014 Apr;35(4):2871-82
pubmed: 24338768
BMC Cancer. 2014 Jan 02;14:1
pubmed: 24383403
Cell Mol Life Sci. 2015 Feb;72(4):821-32
pubmed: 25134913
PLoS One. 2015 Feb 18;10(2):e0117758
pubmed: 25693195
Am J Pathol. 2015 May;185(5):1471-86
pubmed: 25795282
J Gynecol Oncol. 2015 Apr;26(2):87-9
pubmed: 25872889
Int J Gynecol Cancer. 2016 Jan;26(1):43-51
pubmed: 26588231
Oncotarget. 2016 Feb 23;7(8):8823-38
pubmed: 26741506
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11
pubmed: 26970494
J Cancer. 2016 Jun 25;7(10):1295-310
pubmed: 27390605
PLoS One. 2016 Oct 20;11(10):e0164554
pubmed: 27764136
Neoplasma. 2017;64(1):32-39
pubmed: 27881002
J Cancer. 2017 Feb 25;8(5):761-773
pubmed: 28382138
Oncotarget. 2017 Jun 27;8(26):42983-42996
pubmed: 28562334
Cell Signal. 2018 Jan;41:65-74
pubmed: 28931490
Nat Rev Drug Discov. 2017 Dec;16(12):829-842
pubmed: 29075003
BMC Cancer. 2017 Nov 29;17(1):802
pubmed: 29187174
J Int Med Res. 2018 Feb;46(2):723-731
pubmed: 29239277
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Oncogene. 2018 Aug;37(31):4313-4333
pubmed: 29720725
Tumori. 2018 Oct;104(5):330-337
pubmed: 29739299
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Pathol Oncol Res. 2018 Jul 19;:null
pubmed: 30022455
Cell. 2018 Sep 20;175(1):159-170.e16
pubmed: 30241606
Oncotarget. 2018 Oct 12;9(80):35162-35180
pubmed: 30416686
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
pubmed: 3893381
Tumour Biol. 1996;17(4):196-219
pubmed: 8685601